Among the factors driving CML, upregulation of p210 BCR-ABL can activate the MEK-MAPKERK1/2-HNRNP E2 (phosphorylation) pathway and promote the EMT process. This evidence concerns the gene MAP2K7 and chronic myelogenous leukemia, BCR-ABL1 positive.